VDC 2008

Drug Profile

VDC 2008

Alternative Names: VDC2008

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bostwick Laboratories
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Intratumoural, Injection)
  • 03 Nov 2014 Bostwick Laboratories terminates phase I/II trial in Prostate cancer in USA (NCT00753220)
  • 15 Oct 2009 Sangretech's dendritic cell technology licensed to Bostwick Laboratories in certain territories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top